Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by BeenHereBeforeon Sep 18, 2015 9:42am

130 Views

Post# 24115311

RE:RE:Check the box

meeTmyLo wrote: sorry, i am new here, what "box" are you referring to?

--

Strongblow has watched one too many spy thrillers and thinks he can pump up the SP by spinning stories of cloak and dagger agents taping letters to the insides of rubbish bins (aka "the box") containing "life-changing" insider information that the lucky finder can use to trade Antibe to an early retirement.

Translation: He's lying.

Bullboard Posts

Nextech CEO provides company update on Amazon deal and more